Document is current
Any future updates will be listed below
-
Authors
Jons, William A.
Colby, Colin L.
McElroy, Susan L.
Frye, Mark A.
Biernacka, Joanna M.
Winham, Stacey J. http://orcid.org/0000-0002-8492-9102
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R25 BM075148)
- License Information
-
More Information
Article History
Received: 2 July 2019
Accepted: 21 November 2019
First Online: 9 December 2019
Ethics approval and consent to participate
: The research in the Mayo cohort was approved under the title “Mayo Clinic Individualized Medicine Biobank for Bipolar Disorder” by the Mayo Clinic Institutional Review Board (IRB#: 08-008794).
: Not applicable.
: SLMc has received research grants from Alkermes, AstraZeneca, Cephalon, Eli Lilly & Co., Forest, Marriott Foundation, Orexigen Therapeutics, Inc., Naurex, Pfizer, Shire, Takeda Pharmaceutical Company Ltd., and Transcept Pharmaceutical, Inc.; has been a consultant to or member of the scientific advisory boards of Alkermes, Bracket, Corcept, F. Hoffman La Roche, MedAvante, Naurex, Novo Nordisk, Shire, and Teva; and is also an inventor on US patent no. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and, along with the patent’s assignee, University of Cincinnati, Cincinnati, OH, USA, has received payments from Johnson & Johnson, which has exclusive rights under the patent.MAF has received grant support from Pfizer and Myriad and has served as an unpaid consultant for Allergan, Myriad, Sunovion, and Teva Pharmaceuticals.WAJ, CLC, JMB, and SJW declare that they have no competing interests.
